Abstract
Cytokine release syndrome is a serious complication of chimeric antigen receptor-T cell therapy and is triggered by excessive secretion of inflammatory cytokines by chimeric T cells which could be fatal. Following an inquiry into the molecular mechanisms orchestrating cytokine release syndrome, we hypothesize that DeltaRex-G, a tumor targeted retrovector encoding a cytocidal CCNG1 inhibitor gene, may be a viable treatment option for corticosteroid-resistant cytokine release syndrome. DeltaRex-G received United States Food and Drug Administration Emergency Use Authorization to treat Covid-19-induced acute respiratory distress syndrome, which is due to hyperactivated immune cells. A brief administration of DeltaRex-G would inhibit a certain proportion of hyperactive chimeric T cells, consequently reducing cytokine release while retaining chimeric T cell efficacy.
Introduction
Chimeric Antigen Receptor-T (CAR-T) cell therapy is a novel cancer treatment wherein CARs are introduced into a patient’s own harvested T cells and subsequently infused intravenously for the purpose of eradicating cancer (). Factors that limit the efficacy of CAR-T cell therapy include minimal or exaggerated CAR-T cell proliferation, a dysregulated inflammatory tumor microenvironment (TME) and a high baseline tumor burden (Ventin et al., 2024). Cytokine Release Syndrome (CRS) is a severe, potentially fatal, adverse event that could develop in patients receiving CAR-T cell therapy (). Hypothesis: A brief administration of DeltaRex-G, a tumor targeted retroviral vector encoding a cytocidal mutated cyclin G1 gene, would inhibit only the dividing T cells thus reducing cytokine release by hyperactive CAR-T cells while retaining their antitumor efficacy.
CAR-T cell therapy
T cells harvested from the patient are modified with chimeric antigen receptors (CARs) engineered to recognize and bind antigens specific to a patient’s cancer (Sermer and Brentjens, 2019; ). Engineered CAR-T cells equipped to target and eliminate cancer cells are intravenously infused into the patient who has undergone lymphodepletion. Upon recognizing and binding to the target antigen in cancer cells, the activated CAR-T cells eradicate tumor cells while proliferating simultaneously. CAR-T cell therapy has been proven effective in pediatric and adult acute lymphocytic leukemia, B cell lymphoma, mantle cell lymphoma, and multiple myeloma by targeting the Cluster of Differentiation 19 (CD19) or B cell maturation antigen (BCMA) on these malignant cells ().
Currently, there is only one FDA-approved CAR-T cell therapy for solid tumors. The primary challenge to implementing CAR-T cell therapy for solid tumors is tumor heterogeneity and consequent difficulty in ascertaining which antigen, ideally a mutated oncogene, should be targeted (Qin and Xu, 2022). Moreover, solid tumors are often found in tissues with reduced regenerative capacity compared to the hematopoietic system so CAR-T cell targets must be incredibly precise to preserve the maximum amount of healthy tissue (Qin and Xu, 2022; Xia et al., 2018). Two novel receptors enable inducible CAR expression to enhance tumor specificity and prevent CAR-T cell exhaustion, including Synthetic intramembrane proteolysis receptors (SNIPRs) and Signal neutralization by an inhibitable protease (SNIP) (Qin and Xu, 2022; Zhu et al., 2022; ). Additionally, stroma in tumors act as physical barriers and the immunosuppressive tumor microenvironment (TME) further prevents optimal CAR-T cell penetration in solid tumors (). Ongoing research has determined that intratumoral injection of CAR-T cells and a hydrogel containing cytokine and CAR-T cells can overcome the physical impediments to solid tumors and improve CAR-T cell cytotoxicity and efficacy while preserving tumor-specificity (Qin and Xu, 2022; ; ; ). There are currently over fifty clinical trials investigating various solid tumor targets for CAR-T cell therapy--Mesothelin, Carcinoembryonic antigen, Claudin18.2, and Cluster of Differentiation 70 (CD70) are the most common antigens in addition to dual CAR targets to increase tumor specificity (A Phase I, 2016; T Cells Armed With Chimeric, 2016; Phase I, 2017; Phase I Study of Autologous, 2018; ; ; ; ; ; ; ; Phase I Study of EGFR, 2021; A Single, 2021; ; ; ; A Single, 2022; ; ; ; Single-center, 2022a; A Phase I Clinical Study, 2022a; A Safety and Efficacy Clinical, 2022; A Phase I Clinical Study, 2022b; ; A Phase I Clinical Study, 2022d; ; ; A Phase I Clinical Study, 2022c; ; ; ; Single-center, 2022b; ; ; Phase, 2022; A Phase 1, 2023; ; ; ; ; ; Phase I, 2023; ; ; A Phase I Clinical Study, 2023; A Safety and Efficacy Clinical, 2023; ; Phase I Clinical Study of, 2023; A Seamless Phase 1, 2023; ; ; ; ; ; ; ) (A Phase I, 2016; T Cells Armed With Chimeric, 2016; Phase I, 2017; Phase I Study of Autologous, 2018; ; ; ; ; ; ; ; Phase I Study of EGFR, 2021; A Single, 2021; ; ; ; A Single, 2022; ; ; ; Single-center, 2022a; A Phase I Clinical Study, 2022a; A Safety and Efficacy Clinical, 2022; A Phase I Clinical Study, 2022b; ; A Phase I Clinical Study, 2022d; ; ; A Phase I Clinical Study, 2022c; ; ; ; Single-center, 2022b; ; ; Phase, 2022; A Phase 1, 2023; ; ; ; ; ; Phase I, 2023; ; ; A Phase I Clinical Study, 2023; A Safety and Efficacy Clinical, 2023; ; Phase I Clinical Study of, 2023; A Seamless Phase 1, 2023; ; ; ; ; ; ; )
Cytokine release syndrome
CAR-T cell therapy stimulates a robust immune response that can cause cytokine release syndrome (CRS) in patients, which can be fatal. CRS begins as a fever and myalgia two to 3 days after CAR-T cell infusion but can progress to capillary leak, hypoxia, hypotension, tachycardia, pulmonary edema, and pleural edema within 2 weeks of treatment (Sermer and Brentjens, 2019). In dire cases, organ failure and death may ensue. The molecular basis for CRS is excessive secretion of cytokines by T cells (),. One of the core cytokines elevated in CRS patient serum is the inflammatory interleukin-6 (IL-6) produced by monocytes, macrophages, and T-cells (). Patients with high IL-6 levels and large baseline tumor burdens have inflammatory TMEs that prime myeloid cells and macrophages to induce an immune response, and this condition is amplified by CAR-T cell treatment. Elevated IL-6 levels post-treatment have been correlated with diminished response to CAR-T cell therapy and severe CRS (Sermer and Brentjens, 2019). Tocilizumab, an anti-IL-6R antibody, is the current standard of care for mild CRS but corticosteroid therapy like dexamethasone is often required in cases of severe CRS. Recent studies have shown that high dose corticosteroid treatment and early CRS intervention with Tocilizumab and preemptive corticosteroids decreased the risk of severe CRS without adversely affecting CAR-T cell therapy efficacy (; ). Anakirna, an IL-1 receptor antagonist has been identified as another therapeutic for severe CRS (grade 3 or 4) when administered with corticosteroids, and if administered early in combination with Tocilizumab, can prevent CRS (; ). Siltuximab, another anti-IL-6 antibody, has also shown promising results in treating mild CRS (). However, these treatments are not universally effective and as such, a demand for a CRS treatment that will not only mitigate the potentially devastating progression of CRS but could also maximize the potency of the administered CAR-T cell therapy persists ().
DeltaRex-G for cytokine release syndrome
Originally developed as a cancer drug, DeltaRex-G (formerly named Rexin-G, Mx-dnG1) is a tumor targeted retrovector encoding a cytocidal CCNG1 inhibitor gene which inhibits cyclin G1 expression, and consequently, blocks the cancer cell cycle in G0-G1 phase, aborting the cell cycle and resulting in cell death via the apoptosis-mediated pathway (; ). The membrane gp70 envelope of DeltaRex-G was molecularly engineered to display a signature (SIG) protein-binding decapeptide that recognizes and binds to abnormal anaplastic collagenous SIG proteins in the TME, then fuses and enters via the innate amphotropic Pit2 receptor and inhibits/destroys only highly proliferative cells including cancer cells, neoangiogenic cells and stroma-producing fibroblasts (; ). Phase I/II studies in patients with pancreatic adenocarcinoma, sarcomas, and metastatic breast cancers have established a significant association between DeltaRex-G dosage and tumor control/survival advantage (; ; ). During the COVID-19 pandemic, DeltaRex-G was granted FDA Emergency Use Authorization for severe COVID-19 induced CRS and acute respiratory distress syndrome (ARDS) (). CRS from CAR-T cell therapy and COVID-19 develop from excessive stimulation and activation of immune cells and consequent cytokine release resulting in tissue damage.
Recently, we demonstrated the inhibitory activity of DeltaRex-G in cultures of CD4+ CD8+ T cells (See Figure 1). This led to the hypothesis that DeltaRex-G could also inhibit the activity of activated CAR-T cells that cause CRS while retaining CAR-T cell efficacy (See Figure 2). The fact that DeltaRex-G (a retroviral based vector) only integrates in the chromosome of rapidly dividing cells, a property that is common in rapidly dividing cancer cells and proliferating CAR-T cells, is the rationale for using DeltaRex-G in CAR-T induced CRS. Further, DeltaRex-G is not immunogenic, so excessive immune responses are not expected to result from DeltaRex-G treatment. In fact, previous studies in cancer patients showed no development of CRS in DeltaRex-G treated patients and is not expected to cause any serious adverse events, including B-cell aplasia and neurotoxicity which are major sequelae of CAR-T cell therapy (; ; ; ; ).
FIGURE 1
FIGURE 2
Discussion and conclusion
Our hypothesis that a brief administration of DeltaRex-G would reduce the severity of CAR-T cell therapy-induced CRS is supported by the inhibitory activity of DeltaRex-G in transduced CD4 CD8 cell cultures (Figure 1). DeltaRex-G may be used to treat CRS by inhibiting a certain proportion of the proliferative cytokine-releasing immune cells, hence reducing production of IL-6, while retaining the efficacy of unaffected CAR-T cells (Figure 2). Clinical data from cancer patients treated with DeltaRex-G have shown an initial control of tumor growth with eventual tumor shrinkage and attainment of clinical remission after 8 months of DeltaRex-G therapy. Albeit DeltaRex-G has not yet been used to treat CRS, DeltaRex-G has not been reported to cause hematologic nor organ dysfunction in Phase 1 and Phase studies using DeltaRex-G in advanced sarcoma, pancreatic cancer and carcinoma of breast (; ; ; ). Further no vector neutralizing antibodies have formed with prolonged DeltaRex-G therapy, indicating that DeltaRex-G is not immunogenic (; ; ; ). Additionally, no delayed adverse events have been reported in long term (>15 years) cancer survivors with DeltaRex-G treatment (). Nevertheless, a phase 1/2 clinical study is warranted to show the safety and inhibitory activity of DeltaRex-G in patients suffering from steroid-resistant cytokine release syndrome following CAR-T cell therapy.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
GH: Data curation, Formal Analysis, Writing–original draft, Writing–review and editing. EG: Conceptualization, Data curation, Formal Analysis, Supervision, Writing–original draft, Writing–review and editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
The authors are grateful to Heather EG for improvement of the graphic illustration.
Conflict of interest
EMG is co-inventor of the targeted gene delivery system represented by DeltaRex-G which was created and developed at USC Keck School of Medicine, Los Angeles, CA.
The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
A Study to Evaluate the Safety, TolerabilityEfficacy, Preliminary (2023). Pharmacodynamics and immunogenicity of universal CNK-ut cells in patients with advanced solid tumors. Available at: https://clinicaltrials.gov/study/NCT05976906.
2
AdusumilliP. S.CherkasskyL.Villena-VargasJ.ColovosC.ServaisE.PlotkinJ.et al (2014). Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med.6 (261), 261ra151. 10.1126/scitranslmed.3010162
3
An Open (2022). Single-arm clinical study of autologous T cells (CAR-T) targeting B7-H3 chimeric antigen receptor gene in the treatment of patients with advanced gastrointestinal tumors. Available at: https://clinicaltrials.gov/study/NCT05515185.
4
An Open Label (2019). “Single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and cytokinetics of autologous humanized anti-claudin18,” in 2 chimeric antigen receptor T cell in advanced solid tumor subjects. Available at: https://clinicaltrials.gov/study/NCT03874897.
5
A Phase1/phase2, Single-arm (2023). Open-label study of RD14-01 in patients with advanced solid tumors. Available at: https://clinicaltrials.gov/study/NCT05748938.
6
A Phase Ia/Ib (2022). Open-label, single-arm, dose-escalation and expansion study of specific dual-targeting VEGFR1 and PD-L1 CAR-T in cancer patients with pleural or peritoneal metastases. Available at: https://clinicaltrials.gov/study/NCT05477927.
7
A Phase I Investigation of the Safety (2019). Tolerability and immunological effects of T Lymphocytes transduced with an anti-lewis Y (LeY) chimeric antigen receptor gene (LeY-CAR-T) in patients with LeY antigen expressing advanced solid tumours. Available at: https://clinicaltrials.gov/study/NCT03851146.
8
A Phase I Trial to Assess Safety (2020). Tolerability and anti-tumor activity of autologous T cell modified chimeric antigen receptor (CAR) (CCT303-406) in patients with relapsed or refractory HER2 positive solid tumors. Available at: https://clinicaltrials.gov/study/NCT04511871.
9
AsmamawD. T.TirunehG. /M. M.Dessie TerefeG.Tadele AdmasuF.Wale TesegaW.Chekol AbebeE. (2022). Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum. Vaccines and Immunother.18 (6), 2114254. 10.1080/21645515.2022.2114254
10
An exploratory study of αpd1-MSLN-CAR T cells secreting PD-1 nanobodies for the treatment of MSLN-positive advanced solid tumors (2020). Available at: https://clinicaltrials.gov/study/NCT04503980
11
An exploratory study of αpd1-MSLN-CAR T cells secreting PD-1 nanobodies for the treatment of MSLN-positive advanced solid tumors (2022). Available at: https://clinicaltrials.gov/study/NCT05373147
12
A First in human phase I trial of binary oncolytic adenovirus in combination with HER2-specific autologous CAR T cells in patients with advanced HER2 positive solid tumors (2018). Available at: https://clinicaltrials.gov/study/NCT03740256
13
A clinical study on the safety and preliminary efficacy of IMC008 in the treatment of CLDN18.2- positive advanced solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT05837299
14
An exploratory clinical study evaluating the safety and efficacy of anti-CEA-CAR-T cells injection in patients with CEA+ locally advanced and/or metastatic solid tumors (2023a). Available at: https://clinicaltrials.gov/study/NCT06013111
15
An exploratory clinical study evaluating the safety and efficacy of anti-HER2-CAR-T cells injection in patients with HER2+ locally advanced and/or metastatic solid tumors (2023b). Available at: https://clinicaltrials.gov/study/NCT06101082
16
A phase I/II study administering peripheral Blood Lymphocytes transduced with a CD70-binding chimeric antigen receptor to patients with CD70-expressing cancers (2016). Available at: https://clinicaltrials.gov/study/NCT02830724
17
A safety and efficacy clinical study of CEA-targeted CAR-T therapy for CEA-positive advanced malignant solid tumors (2022). Available at: https://clinicaltrials.gov/study/NCT05415475
18
A safety and efficacy clinical study of CEA-targeted CAR-T therapy forCEA-positive advanced/metastatic malignant solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT06010862
19
A seamless phase 1/2 study to evaluate the safety and efficacy of A2B694, an autologous logic-gated TmodTM CAR T, in Heterozygous HLA-A*02 adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express MSLN and have lost HLA-A*02 expression (2023). Available at: https://clinicaltrials.gov/study/NCT06051695
20
A phase 1 dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic solid tumors (2022). Available at: https://clinicaltrials.gov/study/NCT05239143
21
A phase 1 study of FT825/ONO-8250, an off-the-shelf CAR T-cell therapy, with or without monoclonal antibodies (2024). in HER2-Positive or other advanced solid tumorsAvailable at: https://clinicaltrials.gov/study/NCT06241456
22
A phase 1 study to assess the safety and efficacy of LYL797, ROR1-targeting CAR T cells (2022). in Adults with relapsed and/or refractory solid-tumor malignanciesAvailable at: https://clinicaltrials.gov/study/NCT05274451
23
A phase 1/2 study to evaluate the safety and efficacy of A2B530, an autologous logic-gated TmodTM chimeric antigen receptor T cell (CAR T), in heterozygous HLA-A*02 adult subjects with recurrent unresectable (2023). Local. Adv. or Metastatic Solid Tumors That Express CEA Have Lost HLA-A*02 Expr.Available at: https://clinicaltrials.gov/study/NCT05736731
24
A single-arm, open, exploratory clinical study evaluating the safety and efficacy of EGFR/B7H3 CAR-T in patients with EGFR/B7H3-positive advanced solid tumors (lung and triple-negative breast cancer) (2022). Available at: https://clinicaltrials.gov/study/NCT05341492
25
A phase I clinical study of anti-CEA CAR-T therapy in the treatment of CEA-positive advanced malignant solid tumors. (2022a) Available at: https://clinicaltrials.gov/study/NCT05396300
26
A phase I clinical study of CD70-targeting CAR-T therapy in the treatment of CD70-positive advanced/metastatic solid tumors (2022b). Available at: https://clinicaltrials.gov/study/NCT05420545
27
A phase I clinical study of CD70-targeting CAR-T therapy in the treatment of CD70-positive advanced/metastatic solid tumors. (2022c). Available at: https://clinicaltrials.gov/study/NCT05518253
28
A single-center exploratory clinical study to evaluate the safety and efficacy of RD133 in subjects with relapsed or refractory MSLN-positive solid tumors (2021). Available at: https://clinicaltrials.gov/study/NCT05141253
29
A phase I clinical study to assess the safety and efficacy of CD70-targeted CAR-T in the treatment of CD70-positive advanced/metastatic solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT06010875
30
A phase I clinical study to assess the safety and tolerability of CD70-targeting CAR-T in the treatment of CD70-positive advanced/metastatic solid tumors (2022d). Available at: https://clinicaltrials.gov/study/NCT05468190
31
B7-H3-Specific chimeric antigen receptor autologous T-cell therapy for pediatric patients with solid tumors (3CAR) (2021). Available at: https://clinicaltrials.gov/study/NCT04897321
32
BajwaA.ZhaoQ.GeerM. J.MianA.LinC.FrameD.et al (2024). Efficacy of Siltuximab for chimeric antigen receptor T-cell therapy toxicities – a multicenter retrospective Analysis. Transplant. Cell. Ther.30 (2), S201–S202. 10.1016/j.jtct.2023.12.261
33
BrucknerH. W.ChawlaS. P.OmelchenkoN.BrighamD. A.GordonE. M. (2023). Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast. Front. Mol. Med.3, 1105680. 10.3389/fmmed.2023.1105680
34
BrudnoJ. N.KochenderferJ. N. (2016). Toxicities of chimeric antigen receptor T cells: recognition and management. Blood127 (26), 3321–3330. 10.1182/blood-2016-04-703751
35
ChawlaS. P.BrucknerH.MorseM. A.AssudaniN.HallF. L.GordonE. M. (2019). A phase I-II study using rexin-G tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer. Mol. Ther. - Oncolytics12, 56–67. 10.1016/j.omto.2018.12.005
36
ChawlaS. P.ChawlaN. S.QuonD.Chua-AlcalaV.BlackwelderW. C.HallF. L.et al (2016). An advanced phase 1/2 study using an XC-targeted gene therapy vector for chemotherapy resistant sarcoma. Sarcoma Res. Int.3 (1), 1024. Available at: https://austinpublishinggroup.com/sarcoma/fulltext/sarcoma-v3-id1024.pdf.
37
ChawlaS. P.WongS.QuonD.MoradkhaniA.ChuaV. S.BrighamD. A.et al (2022). Three year results of Blessed: expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130). Front. Mol. Med.2, 1092286. 10.3389/fmmed.2022.1092286
38
Chimeric Antigen Receptor T Lymphocytes (CAR-T) (2022). Targeting CEA in the treatment of CEA positive clinical study of advanced malignant solid tumors. Available at: https://clinicaltrials.gov/study/NCT05538195.
39
Clinical study to evaluate the safety and efficacy of U87 CART in treatment of advanced solid tumor (2022). Available at: https://clinicaltrials.gov/study/NCT05605197
40
Clinical trial to evaluate the safety and efficacy of IM96 CAR-T cells therapy in patients with advanced digestive system neoplasms (2022). Available at: https://clinicaltrials.gov/study/NCT05287165
41
Clinical Study of CLDN18 (2022). 2-targeting chimeric antigen receptor-modified autologous T cells in advanced solid tumors with positive CLDN18, 2. Available at: https://clinicaltrials.gov/study/NCT05472857.
42
Efficacy and Safety of Claudin18 (2022). 2CAR-T Adv. Pancreat. Cancer Gastric Carcinoma. Available at: https://clinicaltrials.gov/study/NCT05620732.
43
Exploratory clinical study of PD-1 knockout targeting MUC1 CAR-T cells (AJMUC1) in the treatment of MUC1-positive advanced breast cancer (2022). Available at: https://clinicaltrials.gov/study/NCT05812326
44
Exploratory clinical trial on the safety, efficacy, and pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in claudin 18.2 positive advanced solid malignant tumors: a Single center, Single arm, Dose-increasing Trial (2023a). Available at: https://clinicaltrials.gov/study/NCT05952375
45
Exploratory clinical trial on the safety, tolerability, efficacy, and pharmacokinetics of XKDCT080 in GCC-positive recurrent or refractory solid tumors with Single center, Single arm, and dose escalation.(2023b). Available at: https://clinicaltrials.gov/study/NCT05875402
46
Exploratory study of MSLN-CAR T cells secreting PD1/CTLA-4 nanoantibody for the treatment of advanced solid tumors.(2024). Available at: https://clinicaltrials.gov/study/NCT06248697
47
Exploratory study on the treatment of advanced solid tumor with non-viral vector multi-targeted autosecretory multifunctional antibody CAR-T cell injection (2024). Available at: https://clinicaltrials.gov/study/NCT06327997
48
An exploratory study on the treatment of advanced solid tumors by secretory PD1 nanoantibody targeting mesothelin fast CAR T cells. 2024Available at: https://clinicaltrials.gov/study/NCT06249256
49
FerrerosP.TraperoI. (2022). Interleukin inhibitors in cytokine release syndrome and neurotoxicity secondary to CAR-T therapy. Diseases10 (3), 41. 10.3390/diseases10030041
50
FihA.ArmS. (2022). Open label study to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of autologous CAR T cells targeting BT-001. Patients Adv. Solid Tumors. Available at: https://clinicaltrials.gov/study/NCT05621486.
51
FreyerC. W.PorterD. L. (2020). Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J. Allergy Clin. Immunol.146 (5), 940–948. 10.1016/j.jaci.2020.07.025
52
FTiH (2023). “Phase 1 investigator-initiated trial (IIT) to evaluate the safety, feasibility,” in Cellular kinetics, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18. 2+ GI Tumors. Available at: https://clinicaltrials.gov/study/NCT05981235.
53
GardnerR. A.CeppiF.RiversJ.AnnesleyC.SummersC.TaraseviciuteA.et al (2019). Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood134 (24), 2149–2158. 10.1182/blood.2019001463
54
GazeauN.LiangE. C.WuQ.VoutsinasJ. M.BarbaP.IacoboniG.et al (2023). Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant. Cell. Ther.29 (7), 430–437. 10.1016/j.jtct.2023.04.001
55
GD2/PSMA Bi-specific CAR-T cells for the treatment of GD2 and PSMA positive solid tumors (2022). Available at: https://clinicaltrials.gov/study/NCT05437315
56
GrosskopfA. K.LabaniehL.KlyszD. D.RothG. A.XuP.AdebowaleO.et al (2022). Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci. Adv.8 (14), eabn8264. 10.1126/sciadv.abn8264
57
KalosM.LevineB. L.PorterD. L.KatzS.GruppS. A.BaggA.et al (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med.3 (95), 95ra73. 10.1126/scitranslmed.3002842
58
KorellF.BergerT. R.MausM. V. (2022). Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Med3 (8), 538–564. 10.1016/j.medj.2022.05.001
59
LabaniehL.MajznerR. G.KlyszD.SotilloE.FisherC. J.Vilches-MoureJ. G.et al (2022). Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell185 (10), 1745–1763.e22. 10.1016/j.cell.2022.03.041
60
Larkin (2021). FDA emergency use authorized treatment protocol of DeltaRex-G for severe covid-19 [IND# 27185]. Eur. J. Respir. Med.3 (2). 10.31488/EJRM.119
61
LiuS.ChawlaS. P.BrucknerH.MorseM. A.FedermanN.SrikurejaA.et al (2021). Long term survival following DeltaRex-G/DeltaVax tumor-targeted gene therapy for advanced chemotherapy-resistant malignancies: an academic milestone. Clin. Oncol.6, 1807. 10.25107/2474-1663.1807
62
LiuS.DengB.YinZ.PanJ.LinY.LingZ.et al (2020). Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J.10 (2), 15. 10.1038/s41408-020-0280-y
63
MaudeS. L.BarrettD.TeacheyD. T.GruppS. A. (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J.20 (2), 119–122. 10.1097/PPO.0000000000000035
64
MeleroI.CastanonE.AlvarezM.ChampiatS.MarabelleA. (2021). Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol.18 (9), 558–576. 10.1038/s41571-021-00507-y
65
Mesothelin/GPC3/GUCY2C targeted CAR-T for immunotherapy of pancreatic cancer: phase I clinical trial. (2023). Available at: https://clinicaltrials.gov/study/NCT05779917
66
MorseM.ChawlaS.WongT.BrucknerH.HallF.GordonE. (2021). Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: a case report and literature review. Mol. Clin. Oncol.15 (3), 186. 10.3892/mco.2021.2348
67
OpenAn (2020). Multicenter, phase ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/gastroesophageal junction adenocarcinoma and. Pancreat. Cancer. Available at: https://clinicaltrials.gov/study/NCT04581473.
68
Open-LabelAn (2022). Single-arm, dose-exploration study to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of CT048 in subjects with advanced solid tumors. Available at: https://clinicaltrials.gov/study/NCT05393986.
69
PhaseI. (2022). II study of pan-T booster Co-expressing MSLN CAR T cell therapy in advanced/metastatic solid tumors. Available at: https://clinicaltrials.gov/study/NCT05693844.
70
Phase I clinical study of chimeric antigen receptor T cells (C-13-60) in the treatment of carcinoembryonic antigen (CEA) positive advanced malignant solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT06043466
71
Phase I study of autologous T Lymphocytes expressing GD2-specific chimeric antigen and constitutively active IL-7 receptors for the treatment of patients with relapsed or refractory neuroblastoma and other GD2 positive solid cancers(GAIL-N) (2018). Available at: https://clinicaltrials.gov/study/NCT03635632
72
Phase I/II study of anti-GD2 chimeric antigen receptor-expressing T cells in pediatric patients affected by high risk and/or relapsed/refractory neuroblastoma or other GD2-positive solid tumors (2017). Available at: https://clinicaltrials.gov/study/NCT03373097
73
Phase I/II study of CD70 targeted CAR-T cell treatment in CD70 positive advanced/metastatic solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT05947487
74
Phase I study of EGFR, Targeted tgfβr-KO CAR T cells in the treatment of previously treated advanced EGFR-positive solid tumors (2021). Available at: https://clinicaltrials.gov/study/NCT04976218
75
QinY.XuG. (2022). Enhancing CAR T-cell therapies against solid tumors: mechanisms and reversion of resistance. Front. Immunol.13, 1053120. 10.3389/fimmu.2022.1053120
76
SermerD.BrentjensR. (2019). CAR T‐cell therapy: full speed ahead. Hematol. Oncol.37 (S1), 95–100. 10.1002/hon.2591
77
Single-centerA. (2022a). “Open-label, single-arm clinical study of the safety and efficacy of KD-025 CAR-T therapy,” in Advanced NKG2DL+ solid tumors. Available at: https://clinicaltrials.gov/study/NCT05382377.
78
Single-centerA. (2022b). Open-label, single-arm clinical study of the safety and efficacy of KD-496 CAR-T therapy in advanced nkg2dl+/CLDN18. 2+ Solid Tumors. Available at: https://clinicaltrials.gov/study/NCT05583201.
79
T cells armed with chimeric antigen receptor recognizing EpCAM for patients with advanced solid tumors (2016). Available at: https://clinicaltrials.gov/study/NCT02915445
80
VentinM.CattaneoG.MaggsL.AryaS.WangX.FerroneC. R. (2024). Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review. JAMA Oncol.10 (1), 115–121. 10.1001/jamaoncol.2023.4504
81
XiaH.LiX.GaoW.FuX.FangR. H.ZhangL.et al (2018). Tissue repair and regeneration with endogenous stem cells. Nat. Rev. Mater3 (7), 174–193. 10.1038/s41578-018-0027-6
82
ZhuI.LiuR.GarciaJ. M.Hyrenius-WittstenA.PiranerD. I.AlaviJ.et al (2022). Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell185 (8), 1431–1443.e16. 10.1016/j.cell.2022.03.023
Summary
Keywords
DeltaRex-G, CAR-T cell therapy, cytokine release syndrome, COVID-19, acute respiratory disease
Citation
Haroun G and Gordon EM (2024) DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome. Front. Mol. Med. 4:1461151. doi: 10.3389/fmmed.2024.1461151
Received
07 July 2024
Accepted
06 September 2024
Published
18 September 2024
Volume
4 - 2024
Edited by
Shanchun Guo, Xavier University of Louisiana, United States
Reviewed by
Xiaoming Feng, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Shyam Kumar Gudey, Umeå University, Sweden
Updates
Copyright
© 2024 Haroun and Gordon.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Erlinda M. Gordon, egordon@sarcomaoncology.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.